Abivax SA (FR:ABVX) has released an update.
Abivax SA shares uplifting interim study results showing that patients with moderate to severe ulcerative colitis (UC) maintained clinical remission over two years using a reduced 25 mg daily dose of obefazimod. This maintenance study, part of a longer-term assessment of up to six years, confirms the drug’s efficacy and tolerability. The findings suggest obefazimod could be a promising long-term oral treatment option for UC patients.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
